Culture, arts & science

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased

WEST PALM BEACH, Fla.–(BUSINESS WIRE)– Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from...

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis

– First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients – 4P004 to be evaluated over 3...

Eerste patiënt ingeschreven voor het baanbrekende onderzoek van het National Cancer Institute naar de Shield Multi-Cancer detectietest van Guardant Health

Onderzoek naar de haalbaarheid van het gebruik van multi-kankertests in toekomstige studies wil tot 24.000 deelnemers rekruteren Shield MCD beoordeeld door FDA als onderdeel van...

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participants Shield MCD reviewed by FDA as part...

Kihealth wint Innovation of the Year tijdens ADA 85e Scientific Sessions voor baanbrekende diabetesdiagnostiek

SAINT AUGUSTINE, Fla.–(BUSINESS WIRE)– Kihealth, een leider in moleculaire diagnostiek, heeft vandaag aangekondigd dat het de Innovation of the Year-uitdaging heeft gewonnen tijdens de 85e...

Merck Launches AAW™ Workstation to Advance Lab Automation

New platform powered by Opentrons expands lab automation to accelerate scientific discovery Plug-and-play design for effortless integration into diverse laboratory settings Verified protocols across applications...

Statens Serum Institut Large Danish Study Finds No Link Between Vaccines and Autism or 49 Other Health Conditions

COPENHAGEN, Denmark–(BUSINESS WIRE)– A new Danish study finds no association between aluminum in childhood vaccines and 50 different health conditions, including autism, asthma, and autoimmune...

Groot Deens onderzoek van het Statens Serum Institut vindt geen verband tussen vaccins en autisme of 49 andere gezondheidsaandoeningen

KOPENHAGEN, Denemarken–(BUSINESS WIRE)– In een nieuw Deens onderzoek is er geen verband gevonden tussen aluminium in kindervaccins en 50 verschillende gezondheidsaandoeningen, waaronder autisme, astma en...

PCI Pharma Services gaat volgende groeifase in met strategische investering van Bain Capital, Kohlberg en Mubadala

Investering versnelt PCI’s leidende positie in CDMO en levert levensveranderende therapieën aan patiënten Transactie omvat voortgezette investering van Partners Group PHILADELPHIA–(BUSINESS WIRE)– PCI Pharma Services...

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

– All eligible people with CF in England can now benefit from this medicine – LONDON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that...

Kihealth Wins Innovation of the Year at ADA 85th Scientific Sessions for Groundbreaking Diabetes Diagnostic

SAINT AUGUSTINE, Fla.–(BUSINESS WIRE)– Kihealth, a leader in molecular diagnostics, today announced it has won the Innovation of the Year challenge at the American Diabetes...

PCI Pharma Services Enters Next Phase of Growth With Strategic Investment from Bain Capital, Kohlberg, and Mubadala

Investment Will Accelerate PCI’s Leading Position in CDMO, Delivering Life-Changing Therapies to Patients Transaction Includes Continued Investment from Partners Group PHILADELPHIA–(BUSINESS WIRE)– PCI Pharma Services...

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading...

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

– Both Phase 3 Studies Met all Primary and Secondary Endpoints Demonstrating Statistically Significant Improvements Across Symptoms at All Doses, Building Upon Phase 2b Results...

Elegen en Nutcracker Therapeutics starten test met eerste volledig celvrije productieproces voor RNA-gebaseerde gepersonaliseerde kankertherapieën

Een volledig celvrij proces beoogt de productie van gepersonaliseerde kankertherapieën verder te democratiseren met kortere doorlooptijden en verwaarloosbare bioburden- en endotoxinerisico’s. SAN CARLOS, Calif. &...